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ABSTRACT
Metabolic complications continue to play a major role in the management of HIV infection. Dysli-
pidemia associated with HIV infection and with the use of combined antiretroviral therapy includes 
elevations in triglycerides, reduced high-density cholesterol, and variable increases in low-density 
and total cholesterol. The association between dyslipidemia and specifi c antiretroviral agents has 
been underscored. Multiple pathogenic mechanisms by which HIV and antiretroviral agents lead 
to dyslipidemia have been hypothesized, but they are still controversial. The potential clinical and 
pathological consequences of HIV-associated hyperlipidemia are not completely known, but several 
studies reported an increased risk of coronary artery disease in HIV-positive individuals receiving 
combined antiretroviral therapy. HIV-infected persons who have hyperlipidemia should be man-
aged similarly to those without HIV infection in accordance with the National Cholesterol Educa-
tion Program. Life style changes are the primary target. Statins and fi brates and/or modifi cation in 
antiretroviral therapy are possible approaches to this problem.
Keywords: HIV/AIDS; dyslipidemia; combined antiretroviral therapy; nutrition, Public Health.
[Braz J Infect Dis 2010;14(6):575-588]©Elsevier Editora Ltda.
INTRODUCTION 
Combined antiretroviral therapy (cART) 
significantly modified the prognosis of in-
dividuals infected by the Human Immuno-
deficiency Virus-1 (HIV), with marked im-
provement in morbidity and mortality rates 
worldwide.1-4 Nevertheless, several clinical 
aspects have been developed along with the 
longer longevity of HIV individuals, most 
of them related to other chronic conditions 
or to the antiretroviral treatment (ART).5,6 
Metabolic abnormalities such as insulin re-
sistance and disturbances in glucose homeo-
stasis, modified adiposity physiology with 
lipids alterations might result in clinical 
complications including glucose intolerance 
or diabetes mellitus; altered body fat distri-
bution, with lipoatrophy (loss of subcutane-
ous fat mostly in the face and periphery) or/
and lipohypertrophy (localized fat gain most 
often central and visceral adiposity).7,8
Some of these perturbations can be as-
sociated with ART. Protease inhibitors (PI) 
show direct effect on human adipose and 
specific effects on insulin resistance which 
may contribute to the overall adipose im-
balance and development of lipodystrophy, 
and metabolic syndrome in HIV-positive 
individuals.7-9 In addition, nucleoside re-
verse transcriptase inhibitors (NRTIs) may 
induce mitochondrial dysfunction, which 
could result in effects on adipose tissue, 
lactic acidosis, myopathy, peripheral neu-
ropathy, hepatic steatosis and pancreatitis 
as well.8,10,11 Although less involved, non-
nucleoside reverse transcriptase inhibitors 
(NNRTIs), mainly efavirenz, might be asso-
ciated with metabolic disorders, including 
dyslipidemia.7, 12
Those changes in metabolism and mi-
tochondrial toxicity could eventually be as-
sociated with a greater chance of cardiovas-
cular events and death.13-15 Although some 
association has already been elucidated, the 
relationship between antiretroviral drugs, 
metabolic syndrome, dyslipidemia, and 
cardiovascular events is still far from being 
fully clarified. The purpose of this review is 
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to discuss the development of dyslipidemia and lypodis-
trophy, its relation to cardiovascular events, and its best 
management in individuals with HIV infection.
Overall body changes & lipodystrophy 
syndrome in HIV infection 
These alterations taken together, named “lipodystrophy 
syndrome associated with HIV”, were first described 
in 1998 and included dyslipidemia, lipoatrophy, accu-
mulation of centripetal intra-abdominal fat, and meta-
bolic syndrome.7 The prevalence of the syndrome var-
ies from 11% to 83% in the different studies already 
conducted.16,17
Body changes are associated both with accumula-
tion (lipohypertrophy) and/or with loss (lipoatrophy) 
in body fat. In the case of lipohypertrophy, it is possible 
to find increased abdominal circumference (omental, 
retroperitoneal, and mesenteric), increased breast size, 
and accumulation of fat in dorsocervical region (buffalo 
hump).7,15
On the other hand, lipoatrophy, which is more relat-
ed to nucleoside reverse transcriptase inhibitors (mainly 
thymidinic analogues, zidovudine - ZDV and stavudine 
– d4T), includes loss of subcutaneous fat in the gluteal 
region, arms and legs, along with vascular prominence 
in upper and lower limbs, decreased temporal and peri-
orbital fat pad, and the appearance of nasolabial double 
fold.18,19
These body habitus modifications are usually associ-
ated with alterations in plasma lipids and presence of 
metabolic syndrome. There may be an increase in total 
cholesterol and low-density lipoprotein (LDL-c) frac-
tion, and triglycerides, which are clearly associated with 
pro-atherogenic profile.20,21
Pathophysiology of dyslipidemia with and 
without cART 
Lipids alterations, with increased triglycerides, due in 
part to decreased clearance of very low-density lipo-
protein (VLDL-c) and the reduction of high-density li-
poprotein (HDL-c) in circulation, were reported even 
before the use of antiretroviral drugs.22 Direct lipid 
changes related to HIV disease and/or inflammatory 
factors could partially explain these alterations, which 
could be exemplified by the fact that low CD4+ T-cell 
count might be considered a major atherosclerosis risk 
factor in HIV-infected individuals.22,23
Generally speaking, PIs are associated with dys-
lipidemia, which is highest with ritonavir and boosted 
PIs.9,14,24 Several theories have been proposed to ex-
plain the contribution of PIs in dyslipidemia, although 
none of them explains all aspects. Carr et al.7 proposed 
a theory based on the finding of molecular structural 
homology between the catalytic site of HIV protease 
and two human proteins involved in lipid metabolism, 
the protein binding of retinoic acid cytoplasmic type I 
(CRABP-1 - Cellular Retinoic Acid Binding Protein 1) 
and protein related to the receptor for low-density li-
poprotein (LDL-R). Therefore, most PIs would inhibit 
steps of lipid metabolism, probably depending on the 
gene expression of the involved receptor. PI connected to 
CRABP-1 would decrease the activation of the receptor 
of 9-cis retinoic acid and dimerization with the recep-
tor activated by the peroxisome proliferator γ (PPARγ 
- Peroxisome Proliferator Activated Receptor-gamma), 
which has a key role in the differentiation of adipocytes 
and apoptosis of these cells, and further improves the 
peripheral sensitivity to insulin. Such changes would 
lead to the release of lipids into the circulation and hy-
perlipidemia. 
Another proposed mechanism is the inhibition of the 
activity of the plasmatic lipoproteic lipase by PI, which 
binds to the LDL-R. The difficulty in capturing the chy-
lomicron and the hepatic clearance of triglycerides by 
complex endothelial lipoprotein lipase-LRP, in turn, 
would mean a lower uptake by the liver and triglycerides 
by cleavage of the fatty acids in glycerol. However, this 
hypothesis has yet to be confirmed.25
In the same way factors that could increase the activ-
ity of the protein link to the sterol regulatory element 
1 (SREBP-1 - Sterol Regulatory Element Binding Pro-
tein 1) might lead to increased lipogenesis and increased 
production of VLDL-c. Experiments done in animals 
with ritonavir showed marked increase of VLDL-c in the 
presence of a diet rich in fat, and a significant increase 
in the levels of liver apoliprotein B (Apo B).26 Therefore, 
the increase in triglycerides caused by ritonavir could be 
related to the enhancement in the production of hepatic 
lipoprotein, by inhibiting the proteasome-mediated 
degradation of Apo B and SREBP-1 in the liver.27
Similarly, genetic predisposition may explain, in 
part, the variability between patients in relation to the 
effects of PIs on the metabolism of lipids. Most indi-
viduals when exposed to ritonavir may have significant 
increases in plasma levels of triglycerides, while in oth-
ers this elevation does not occur.28,29 However, the genes 
involved in these phenomena are not yet known.
Generally, PIs (except atazanavir) seem to inhibit the 
function of GLUT-4 in the transport of glucose, which 
reduces the uptake of glucose mediated by insulin in 
skeletal muscles and in adipocytes, which can lead to 
changes in lipid metabolism.9,30,31 
PI can also induce insulin resistance by the inhibition 
of translocation of SREBP-1c, directly or indirectly via 
PPARγ receiver.32 SREBP-1 regulates the growth and syn-
thesis of glucose, differentiation and maturation of adi-
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pocytes and increased glucose through the adipocytes. 
The process of adipocyte differentiation may increase 
the synthesis and secretion of adiponectin, a cytokine 
that sensitizes insulin action.33 Since PPARγ is preferen-
tially expressed in peripheral adipocytes, it is expected 
that the inhibition of protein carrier of retinoic acid by 
the PIs could result in apoptosis and damaged differen-
tiation of adipocytes contributing to the development of 
changes in the fat distribution and insulin resistance.34 
Furthermore, the class of NRTIs can also be associ-
ated with the development of dyslipidemia and insulin 
resistance and their consequences, as already explained. 
The NRTIs (mainly the thymidine analogues, d4T and 
ZDV) reduce the synthesis of mitochondrial DNA by in-
hibiting DNA polymerase gamma.35 As a result there is 
a depletion of mitochondrial DNA, enzyme deficiency, 
oxidative phosphorylation and induction of subcutane-
ous adipocytes apoptosis.10,11,36
Atherosclerotic disease in HIV infection and 
AIDS
Many studies have demonstrated an association between 
cART and increased risk in coronary events when com-
pared to the general population, which may be related to 
dyslipidemia and to the duration of cART exposure.13,14,37,38 
The largest study of cardiovascular epidemiology in 
HIV-infected individuals on cART is the Data Collection 
on Adverse Effects of Anti-Retroviral Drugs (D:A:D), a 
multicohort study. D:A:D has shown an increased rela-
tive risk of acute myocardial infarction of 1.26 (26% 
more) per year of exposure to cART in the first four to 
six years, and the recent use (up to 6 months) of abacav-
ir, didanosine, lopinavir or indinavir were independent-
ly associated with increased risk.13,14,38 It is important to 
consider that traditional risks, such as tobacco smoking, 
dyslipidemia, diabetes and hypertension, were also in-
creased in these studies. In order to estimate the 10-year 
cardiovascular risk in relation to the time of cART ex-
posure, the Framingham score was evaluated in D:A:D 
participants.40 With the caveat that Framingham scores 
could under evaluate the coronary risk in HIV-infected 
individuals, this study showed that the chance for first 
cardiovascular event increased with time of exposure 
to ART (relative risk per year of exposure: 1.26, 95%, 
CI: 1.15 to 1.38).
There is only one major study that found no differ-
ence in cardiovascular disease in HIV-infected individu-
als on cART.39 Although controversial, this was a retro-
spective analysis of 36,766 HIV-infected individuals on 
cART, between 1993 and 2001, with respect to overall 
mortality, mortality for specific cardiovascular and cere-
brovascular events, and rates of hospitalization. Hospi-
tal admissions for cardiovascular and brain diseases and 
the fatality rate decreased (1.7% to 0.9%, 21.3% to 5.0% 
from 1995 to 2001, respectively). However, the study 
sites were known to not offer good cardiovascular care, 
which could lead to a selection bias in the study. Also, it 
has been noticed that the prescription of lipid reducing 
agents gradually increased over the time. 
In the Study of Strategies for Addressing the Anti-
Retroviral Therapy (SMART), individuals were random-
ized to continue cART or to temporarily interrupt their 
treatment when the CD4 cell count was higher than 
350 cells/mm3 and for restarting when it had fallen to 
less than 250 cells/mm3.41 This study was stopped pre-
maturely by the high incidence of adverse outcomes 
including fatal and non-fatal cardiovascular events in 
the group with cART interruption. Given the general 
impression that cART is associated with increased risk 
of cardiovascular disease, it would be expected to see a 
reduction of these events. However, the relative risk of 
these complications was 1.5 times greater in the group of 
patients discontinuing cART compared to the group that 
remained on therapy. This reinforces the hypothesis in 
which HIV itself is considered an independent risk factor 
for cardiovascular disease.
Incidence of dyslipidemia in HIV infection and 
AIDS
Before cART, the main metabolic alteration was related 
to wasting, with protein-energy malnutrition, charac-
terized by depletion of lean mass and fat. Unfavorable 
changes in lipid profile, with reduction in the levels of 
HDL-c and mild elevation in the levels of triglycerides, 
also occurred in advanced disease because of changes in
inflammatory cytokines, phenomenon also found 
in other chronic inflammatory disorders not caused by 
HIV.22 
Unfortunately, as already mentioned, cART can be 
associated with the development of dyslipidemia. The 
abnormalities in lipid profile generally occur after the 
beginning of ART, frequently between the third and 
sixth month, but its emergence may be early in regimens 
containing PIs.9,42,43 The prevalence of dyslipidemia in 
HIV-infected individuals on cART varies from 30% to 
80% depending on drug combination and diagnostic 
definition criteria, and the most common include hy-
pertriglyceridemia (40% to 80%), and hypercholester-
olemia (10% to 50%).16,24,44 
Changes in lifestyle and dyslipidemia in HIV 
infection and AIDS
Scientific evidence about the effectiveness of diet indi-
cates that a limited energy intake from simple sugars and 
fats, the replacement of saturated fat and trans unsatu-
rated fat by the increased consumption of fruits, vegeta-
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bles, whole cereals, and nuts confer significant benefits 
for the health of general population. Epidemiological 
surveys have shown the synergistic effect of changes in 
lifestyle, such as “healthy” diet that provide a “shield” 
against the development of several non-transmissible 
chronic diseases, including cardiovascular disease, hy-
pertension, diabetes mellitus, obesity and dyslipidemia 
in the non-HIV population.46,47 Although epidemiologi-
cal surveys have not yet been conducted among HIV-
infected induviduals, most studies support changes in 
lifestyle as a major goal to be addressed.48-55 Also, as ex-
pected, better results were achieved in individuals with 
adherence to diet modifications. 
Our group assessed the impact of physical condi-
tioning and diet on low levels of lipids in HIV-infected 
individuals with dyslipidemia and lipodystrophy. Al-
though of short duration and dealing primarily with 
aerobic exercise and therapeutic intervention, there was 
no consistent changes in plasma lipids.49 Fitch et al., 
evaluated whether changes in lifestyle could have ben-
eficial effect on cardiovascular risk factors in patients on 
HAART and manifestations of the metabolic syndrome. 
After six months, despite improvement in the physical 
condition, diet habit and abdominal circumference in 
the group that changed the way of life, there was no sig-
nificant improvement in plasma lipids compared to the 
control group.50 
The amount of fiber, alcohol and fat in diet may 
play an important role in dyslipidemia associated with 
HIV.50-55 Some components of diet, such as saturated, 
monounsaturated and polyunsaturated fat, fiber and 
alcohol, were directly linked to insulin resistance and 
hypercholesterolemia, whereas diet rich in fiber was in-
versely associated.51,52 Also, high amounts of alcohol were 
linked to high levels of LDL. These associations were in-
dependent of age, sex, distribution of body fat and time 
of exposure to PIs. 
Barrios et al. prospectively evaluated the effective-
ness of a low-fat diet in the reduction of cholesterol and 
triglycerides in 230 HIV-infected individuals. Those 
with good adherence to diet had a reduction of 11% and 
10% in the levels of cholesterol and in 12% and 23% in 
the levels of triglycerides after 3 and 6 months, respec-
tively. Adherence to diet was also associated with sig-
nificant weight loss. The impact on the abovementioned 
metabolic parameters was more noticeable among indi-
viduals on PIs and after 6 months (cholesterol decreased 
13% and 22% and triglycerides 15% and 49% at 6 and 6 
months, respectively).54
The management of HIV-infected individuals with 
dyslipidemia needs to be validated, specified and indi-
vidualized. Currently, the recommendations of the Adult 
AIDS Clinical Trials Group (ACTG), based on the NCEP, 
must be followed for the prevention and management 
of dyslipidemia associated with cART. These guidelines 
are primarily directed towards a healthy way of life, with 
physical activity and a balanced diet,24 but this approach 
is empiric as there is no sufficient clinical evidence to 
support it. 
Omega 3 and dyslipidemia in the acquired 
immunodeficiency syndrome
It is known that omega 3 (fish oil) is associate with a re-
duction in cardiovascular events in general population.56 
Diet supplementation with omega 3 and exercise were 
compared in HIV-infected patients who had triglyceride 
levels greater than 200 mg/dL. After 16 weeks of follow-
up, there was no significant difference in the levels of 
triglycerides between groups. However, LDL-c levels did 
significantly increase in the fish oil arm, but not in the 
diet and exercise arm (22% versus 18%, respectively).57
Gerber et al. randomized 100 patients with hypertrig-
lyceridemia on cART to receive fenofibrate or fish oil for 
eight weeks. Of 47 subjects on fish oil, 4 (8.5%) and of 
48 on fenofi brate, 8 (16.7%) achieved TG < 200 mg/dL.59 
When both interventions were offered to individuals 
who have not responded, 22% more reached target lev-
els of triglycerides. As observed in the other study, there 
was an increment of LDL-c.57,58
Another study also demonstrated the benefits of poly-
unsaturated fatty acids omega 3 (PUFA) in HIV-infect-
ed individuals with triglyceride levels above 300 mg/dL. 
In the eighth week, patients who received PUFA showed 
an average reduction of 25% in the levels of triglycerides 
compared to a 1% increase in those who received the 
paraffin oil (p = 0.0033). In this study, nutritional guid-
ance was also significantly important to reduce triglyc-
erides.59 
Hypolipemiants drugs in HIV infection and 
AIDS
Drug therapy becomes necessary when changes in life-
style are not effective in reducing lipid level.24 Statins 
are the agents of choice (to reduce total cholesterol and 
LDL-c) and fibrates (to reduce triglycerides levels), es-
pecially gemfibrozil, fenofibrate and bezafibrate.24,60-74 In 
extreme condition, the association of both classes could 
be tried. However, these should be avoided as they 
could be associated with adverse effects, potential drug 
interactions, adherence problems and increased treat-
ment costs.
There are few data from clinical trials with the use 
of statins in HIV-infected individuals. Most statins are 
metabolized by the cytochrome P450, isoenzyme 3A4 
(CYP3A4), which is inhibited by most PIs. This could 
lead to an increase in serum levels of the statin and 
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higher chance to adverse effects. Some statins are not 
recommended and others are considered safe to use 
along with cART.24,60 Simvastatin and lovastatin, which 
are highly metabolized by CYP3A4, are contraindicated; 
atorvastatin and rosuvastatin can be used with caution; 
and although with the lowest potency, pravastatin and 
fluvastatin could be more safely used, as they are mostly 
not metabolized by CYP3A4 isoenzyme.24,61 
Henry et al. investigated the effect of atorvastatin 
and gemfibrozil compared to diet and exercise in HIV-
positive individuals with hypertriglyceridemia. Diet and 
exercise decreased the levels of total cholesterol and 
triglycerides in 11% and 21% respectively, while gem-
fibrozil in combination with atorvastatin reduced the 
levels of total cholesterol and triglycerides by 30% and 
60% respectively.47 Similarly, Miller et al. showed that 
gemfibrozil and diet (low saturated fat) decreased serum 
levels of triglycerides in 120 mg/dL, when compared to 
diet (p = 0.08).63
To evaluate the effectiveness of fibrates (bezafibrato, 
gemfibrozil and fenofibrate) and statins (pravastatin 
and fluvastatin) in the management of hyperlipidemia 
associated with the administration of PI-based cART, 
Calza et al. followed 288 dislipidemic individuals sub-
mitted to diet and physical activity. At the end of at least 
three months, 61% of the subjects responded to diet, and 
106 (39%) in whom lipid levels did not decrease, were 
randomized to either one hypolipemiant drug. Individ-
uals treated with fibrates had a reduction of 41% and 
23%, in the levels of triglycerides and total cholesterol, 
respectively, after six months of treatment, and 41% and 
22% in one year (LDL-c decreased by 23% and HDL-c 
increased by 20%). In the statin group there was a 36% 
and 27% reduction of triglycerides and total cholesterol 
after 6 months, and 34% and 25% after one year (LDL-c 
reduced by 26% and HDL-c increased by 24%).60
Recently the effectiveness of switching PIs for NNRTI 
(nevirapine or efavirenz) or hypolipemiants (statin 
and fibrate) was evaluated in 138 patients during 12 
months.64 At the end of follow-up, there was a reduction 
in the levels of triglycerides by 25% in the group with 
nevirapine, 9% in the group with efavirenz, 41% with 
pravastatin and 47% with bezafibrate, which favoured 
hypolipemiants. Similar results were found with respect 
of total cholesterol and LDL-c. This study showed that 
in mixed hyperlipidemia associated with cART and non-
responsive to changes in lifestyle, treatment with a statin 
or a fibrate was more effective than switching PIs for 
NNRTIs. 
A Brazilian study assessed the behavior of lipid pro-
file before and after treatment with bezafibrate in 84 
subjects with persistent hypertriglyceridemia that was 
not controlled with diet only. There was a significant 
reduction in levels of triglycerides (from 640 mg/dL 
to 372 mg/dL, p < 0.0001) and total cholesterol (from 
253 mg/dL to 228 mg/dL, p < 0.01).65
In order to evaluate the effect of new drugs for lower-
ing lipids not entirely metabolized by CYP3A4 in HIV-
positive population, Calza et al. administered 10 mg/day 
of rosuvastatin in 16 patients with hypertriglyceridemia 
that were taking lopinavir/ritonavir. After 24 weeks 
there was an average reduction in the levels of total cho-
lesterol and triglycerides of 21.7% and 30.1% respec-
tively.64 Similarly, Van der Lee et al. found a reduction 
in the levels of total cholesterol and LDL-C, 27.6% and 
31.8%, respectively (the levels of rosuvastatin were 1.6 
times higher when compared with healthy volunteers).66 
In both studies the drug was considered relatively safe.
Palacios et al. evaluated the efficacy and safety of 
atorvastatin 10 mg for the treatment of hypercholester-
olemia in 20 patients using antiretroviral therapy for at 
least 12 months. Atorvastatin was safe and effective with 
a significant reduction in the levels of total cholesterol 
and LDL-c after 24 weeks of follow-up.67
Ezetimibe can be as effective as fluvastatin to reduce 
LDL-c69 and can have additive effect on lipids when ad-
ministered along with other hypolipemiant drug.69,70,75 
On the basis of all relevant published data, we have 
prepared a concise, evidence-based update of the cur-
rent understanding of the clinical presentation. Tables 1 
and 2 summarize results of trials conducted to treat dys-
lipidemia. Although less effective than hypolipemiant 
agents, sometimes could be easier to change ART due 
to problems with adherence, risk of interactions and/or 
increasing toxicity.76-80
Management of dyslipidemia in HIV-positive 
individuals
In summary, treatment guidelines for the management 
of dyslipidemia in these patients are the same as those 
recommended for the general population.24 Life style 
modification is the primary and first target of treat-
ment. Drug treatment for dyslipidemia in HIV-infected 
persons on cART can be complex, given the possible 
drug interactions, toxicity, intolerance, and even impair 
adherence. There is strong enough evidence to support 
the use of fibrates to treat hypertriglyceridemia. They 
are relatively safe and not associated with major side ef-
fects. They also can decrease to some extend cholesterol 
level as well. On the other hand, hypercholesterolemia 
drug management is not so simple. Statins, the preferred 
drug class to decrease cholesterol, might be associated 
with side effects and drug interaction which could in-
terfere to cART treatment. While fluvastatin and pravas-
tatin are safe, although not very effective, simvastatin 
and lovastatin are contraindicated in individuals on 
Sprinz, Lazzaretti, Kuhmmer et al.
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cART which includes PI and/or ritonavir (risk of se-
vere adverse event). The statin plasma levels are high-
ly increased when used along with these agents. The 
other statins atorvastatin and rosuvastatin have better 
therapeutic index; they are more efficacious and could 
be more safely used. Conversely, the non-nucleosides 
efavirenz, and nevirapine can induce CYP3A4, which 
would decrease the statin levels. Therefore, the statin 
dose should be titrated in order to achieve the desir-
able target. Therefore, we still need to develop more 
friendly and safe antiretroviral drugs while a cure is 
not yet found to HIV infection.
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